VCAM and TF in the control and sickle mouse. VCAM (A) and TF (B) in the C57BL6 control and NY1DD sickle mice, which were pretreated with TSA for 3 days; hBERK1 mice were treated for 3, 7, or 21 days only at ambient air. NY1DD mice were studied at air and after H/R, as indicated, whereas hBERK1 animals were studied only at air. (A) *P < .001; **P < .001; #P = .027; &P = .019. (B) *P < .001; #P = .029; and &P < .001. Number of experimental animals, for bars left to right: top panel, 8, 4, 8, 4, 4, 6, 4, 6, 6, 6, 6, and 6; bottom panel, 4, 4, 4, 4, 4, 6, 4, 6, 6, 6, 6, and 6. These data illustrate that TSA decreases expression of VCAM and TF when given as pretreatment before the H/R-induced boost in endothelial stimulation (NY1DD model). In the hBERK1 model, with already-boosted VCAM and TF at ambient air, the TSA reduced VCAM but not TF unless it was given for a prolonged period. Error bars show ±SD.